Cost-Effectiveness of Sacubitril-Valsartan Compared to Angiotensin-Converting Enzyme Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction.
Ratih Puspita FebrinasariStefanus E PutraMuhammad HafizhanAri N ProbandariPublished in: Journal of pharmacy practice (2022)
The use of sacubitril/valsartan associates with longer life expectancy and incremental cost-effectiveness ratio than angiotensin-converting enzyme inhibitors.